Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialGeorgina V. Long, Dirk Schadendorf, Uwe Trefzer et al.|The Lancet Oncology|2012Cited by 906
Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma studyLeila Khoja, Anthony M. Joshua, Sapna P. Patel et al.|Annals of Oncology|2019Cited by 282
Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective <i>BRAF</i> InhibitionLisa Zimmer, Dirk Schadendorf|Journal of Clinical Oncology|2012Cited by 225
Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanomaBatool Shannan, Alexander Roesch, Johann Matschke et al.|European Journal of Cancer|2019Cited by 26